Welcome to our dedicated page for Tema Healthcare AI ETF news (Ticker: HLTH), a resource for investors and traders seeking the latest updates and insights on Tema Healthcare AI ETF stock.
Cue Health Inc. news covered the company's healthcare technology business, including diagnostic-enabled care, at-home and point-of-care molecular testing, telehealth services, FDA-related product developments, earnings releases, and governance actions. Recurring updates described its COVID-19 and Mpox diagnostic products, customer categories across public agencies and private-sector healthcare users, and cost-reduction or operational efficiency actions.
Later Cue Health news documented the company's Chapter 7 bankruptcy filing and planned wind down, including the intended sale of assets and creditor-payment process under the Bankruptcy Code.
Tema Healthcare AI ETF (NASDAQ: HLTH) is a newly launched, actively managed, pure-play ETF focused on artificial intelligence applications in healthcare. According to Tema, the fund targets companies using AI in drug discovery, diagnostics, clinical robotics, and technologies that improve patient care.
HLTH is advised by Tema ETFs and sub-advised by Tidal Investments, with portfolio management led by physician-investor Dr. David Song, MD, PhD, CFA. The ETF lists on NASDAQ on July 21, 2026, has a gross expense ratio of 0.75%, and trades under ticker HLTH. As of July 21, 2026, top holdings include 10x Genomics, Cytokinetics, Illumina, Intuitive Surgical, and Vertex Pharmaceuticals, each weighted around 4–5%. The fund is sector-focused in healthcare and information technology and carries associated concentration, regulatory, and innovation risks highlighted in its prospectus.
Made Scientific (HLTH) appointed Ted Dolan and Soyoung Park to its Board to support scale-up and commercial readiness in cell therapy manufacturing. The company said the expanded Board brings CDMO operations, commercialization, strategy, and financial expertise as it expands GMP capacity at its Princeton, NJ campus and partners with GC Corporation.
Cue Health (Nasdaq: HLTH), a healthcare technology company, has filed for Chapter 7 bankruptcy in the District of Delaware, aiming to wind down its business. Despite efforts to reduce costs and find additional financing or strategic transactions, the Board of Directors, after thorough review and consultation, determined that filing for Chapter 7 was in the best interest of stakeholders. A bankruptcy trustee will be appointed to manage the liquidation of assets to pay creditors. Cue Health expressed gratitude to its employees, customers, and vendors for their contributions and partnerships.
Cue Health (Nasdaq: HLTH) has received a warning letter from the FDA regarding its Emergency Use Authorized (EUA) COVID-19 test. The healthcare technology company is currently evaluating the letter and determining an appropriate response. Further details will be provided in the coming days.
Cue Health Inc. (HLTH) is set to release its first quarter 2024 financial results on May 13, 2024, without hosting a conference call.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.